Inhaled corticosteroids in early COVID-19-A tale of many facets.
作者信息
Klimek Ludger, Akdis Cezmi A, Jutel Marek, Zuberbier Torsten, Bousquet Jean
机构信息
Center for Rhinology and Allergology, Wiesbaden, Germany.
Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich - Christine Kühne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.
出版信息
Allergy. 2021 Nov;76(11):3540-3542. doi: 10.1111/all.15041. Epub 2021 Aug 27.
Abstract
摘要
相似文献
1
Inhaled corticosteroids in early COVID-19-A tale of many facets.COVID-19早期的吸入性糖皮质激素——多方面的故事
Allergy. 2021 Nov;76(11):3540-3542. doi: 10.1111/all.15041. Epub 2021 Aug 27.
2
The use of inhaled corticosteroids in early-stage COVID-19.吸入性糖皮质激素在新冠肺炎早期的应用。
Lancet. 2021 Sep 4;398(10303):818-819. doi: 10.1016/S0140-6736(21)01809-2. Epub 2021 Aug 10.
3
Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial.吸入性皮质类固醇下调 COPD 中与 SARS-CoV-2 相关的基因：一项随机对照试验的结果。
Eur Respir J. 2021 Jul 29;58(1). doi: 10.1183/13993003.00130-2021. Print 2021 Jul.
4
COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial Effect of Inhaled Corticosteroids?新型冠状病毒肺炎、哮喘与吸入性糖皮质激素：吸入性糖皮质激素的又一有益作用？
Am J Respir Crit Care Med. 2020 Jul 1;202(1):8-10. doi: 10.1164/rccm.202005-1651ED.
5
[COVID-19 and asthma].[新型冠状病毒肺炎与哮喘]
Rev Med Liege. 2020;75(S1):130-132.
6
COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence.COVID-19 风险和结局在接受生物制剂或全身皮质类固醇治疗的成年哮喘患者中的：全国真实世界证据。
J Allergy Clin Immunol. 2021 Aug;148(2):361-367.e13. doi: 10.1016/j.jaci.2021.06.006. Epub 2021 Jun 15.
7
Role of corticosteroids in the treatment of COVID-19 infection.皮质类固醇在新型冠状病毒肺炎感染治疗中的作用。
Minerva Anestesiol. 2020 Nov;86(11):1249-1250. doi: 10.23736/S0375-9393.20.14864-8. Epub 2020 Jun 12.
8
Reply to Lipworth : Inhaled Corticosteroids and COVID-19.对利普沃思的回复：吸入性糖皮质激素与2019冠状病毒病
Am J Respir Crit Care Med. 2020 Sep 15;202(6):900-902. doi: 10.1164/rccm.202006-2129LE.
9
CJEM journal club: corticosteroids use for critically ill COVID-19 patients.《加拿大急诊医学杂志》期刊俱乐部：皮质类固醇用于危重症COVID-19患者
CJEM. 2021 Mar;23(2):162-163. doi: 10.1007/s43678-020-00056-w. Epub 2021 Jan 11.
10
Inhaled corticosteroids for the treatment of COVID-19.吸入性糖皮质激素用于治疗新型冠状病毒肺炎
Clin Exp Allergy. 2023 Oct;53(10):986-988. doi: 10.1111/cea.14368. Epub 2023 Jul 2.
引用本文的文献
1
Effect of asthma, COPD, and ACO on COVID-19: A systematic review and meta-analysis.哮喘、COPD 和 ACO 对 COVID-19 的影响：系统评价和荟萃分析。
PLoS One. 2022 Nov 1;17(11):e0276774. doi: 10.1371/journal.pone.0276774. eCollection 2022.
本文引用的文献
1
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.吸入用布地奈德治疗早期 COVID-19（STOIC）：一项 2 期、开放标签、随机对照试验。
Lancet Respir Med. 2021 Jul;9(7):763-772. doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9.
2
Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper.COVID-19 大流行期间慢性鼻-鼻窦炎患者的管理。- EAACI 立场文件。
Allergy. 2021 Mar;76(3):677-688. doi: 10.1111/all.14629.
3
Asthma-associated risk for COVID-19 development.哮喘与 COVID-19 发展的相关性风险。
J Allergy Clin Immunol. 2020 Dec;146(6):1295-1301. doi: 10.1016/j.jaci.2020.09.017. Epub 2020 Sep 28.
4
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020).ARIA-EAACI关于哮喘与2019冠状病毒病的声明（2020年6月2日）
Allergy. 2021 Mar;76(3):689-697. doi: 10.1111/all.14471. Epub 2020 Sep 21.
5
Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement.2019冠状病毒病感染患者变应性鼻炎的鼻内糖皮质激素：ARIA-EAACI声明
Allergy. 2020 Oct;75(10):2440-2444. doi: 10.1111/all.14302.
6
The placebo effect in asthma.哮喘的安慰剂效应。
Curr Allergy Asthma Rep. 2014 Aug;14(8):456. doi: 10.1007/s11882-014-0456-2.
Zotero 插件